MedTrace Logo

Evaluate Recovery of Testosterone for Patients Using Eligard

NCT01136226 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-10-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.

Conditions

Interventions

DRUG

Eligard (TM)

Eligard (TM) 22.5 mg administered at baseline and Month 3

Sponsors & Collaborators

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • Chesapeake Urology Research Associates

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2009-06-30
Completion
2009-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136226 on ClinicalTrials.gov